Allstate Corp Apellis Pharmaceuticals, Inc. Transaction History

Allstate Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$35.46 - $54.12 $237,369 - $362,279	-6,694 Closed	0 $0
Q4 2021 Feb 15, 2022	BUY	$30.74 - $49.16 $205,773 - $329,077	6,694 New	6,694 $316,000
Q3 2021 Nov 15, 2021	SELL	$31.4 - $69.84 $177,441 - $394,665	-5,651 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$40.9 - $64.9 $2,903 - $4,607	71 Added 1.27%	5,651 $357,000
Q1 2021 May 14, 2021	BUY	$40.8 - $57.39 $5,018 - $7,058	123 Added 2.25%	5,580 $239,000
Q4 2020 Feb 12, 2021	BUY	$30.79 - $57.2 $168,021 - $312,140	5,457 New	5,457 $312,000
Q3 2020 Nov 13, 2020	SELL	$25.89 - $33.65 $171,495 - $222,897	-6,624 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$24.8 - $38.49 $164,275 - $254,957	6,624 New	6,624 $216,000

308

115M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Allstate Corp, based on Form 13F filings with the SEC.

Stay updated on Allstate Corp with notifications on news.